image description

Tag: PhD

Bacteria Could be to Blame for Autoimmune Attacks

March 12, 2018 Innovative novel research, co-funded by the Lupus Research Alliance, has produced a significant discovery about the role of bacteria and points to the potential for a vaccine or treatment that might prevent an autoimmune attack by suppressing specific bacteria. Led by Dr. Martin Kriegel at Yale University, the study was published today […] Read More

LRA Announces Partners on the First Anniversary of the Lupus Landmark Study

April 11, 2024 The Lupus Research Alliance (LRA) and its clinical research affiliate Lupus Therapeutics (LT) are pleased to announce the group of industry partners working together on the implementation of the Lupus Nexus. The Lupus Nexus, one of LRA’s most ambitious and groundbreaking endeavors, is a first-of-its-kind lupus registry, biorepository, and data exchange platform […] Read More

Recent Discoveries Shedding Light on Why Women Are at a Greater Risk for Lupus

March 20, 2024 Lupus is a complex autoimmune disease affecting millions worldwide with a staggering gender imbalance — about 9 of 10 people with lupus are women. Underlying biological, hormonal, or environmental factors likely contribute to why lupus affects females more often. Understanding why women are at greater risk for lupus could unlock novel treatments […] Read More

Lupus Industry Council Study Finds Inconsistency of ANA Tests

Lupus Industry Council Study Finds Inconsistency of ANA Tests A new study funded by the Lupus Research Alliance Lupus Industry Council shows that not all individuals who have been diagnosed with lupus remain positive for antinuclear antibodies (ANA) despite the long-held scientific belief to the contrary. Importantly, this study also reveals that whether a person […] Read More

Lupus Research Alliance Applauds U.S. FDA Approval of AstraZeneca’s anifrolumab-fnia (Saphnelo™) for Systemic Lupus Erythematosus (SLE)

  First in New Class of Drugs in More than a Decade for SLE Targeting Type 1 Interferons NEW YORK, NY. August 2, 2021. The Lupus Research Alliance (LRA) is particularly excited about the U.S. Food and Drug Administration (FDA) approval of anifrolumab-fnia (Saphnelo™), a first-in-class type I interferon receptor antagonist indicated for adults with […] Read More

Project CHANGE Launches Pilot Programs in Atlanta, Nashville, and Philadelphia to Increase Diversity in Lupus Clinical Research

New York, NY. June 29, 2023. Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, today announced the launch of three pilot research initiatives for Project CHANGE, a community-driven approach to address systemic challenges contributing to the underrepresentation of people of color, particularly Black people, in lupus clinical trials. The sites selected to […] Read More
Stay informed about events, research developments, and ways you can help. Sign up for updates